Stock LENZ LENZ THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News LENZ Therapeutics, Inc.

Equities

LENZ

US52635N1037

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-23 pm EDT 		5-day change 1st Jan Change
15.72 USD -14.61% Intraday chart for LENZ Therapeutics, Inc. -0.76% 0.00%
Apr. 15 Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target MT
Apr. 15 William Blair Starts LENZ Therapeutics With Outperform Rating MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
LENZ Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates
GL
LENZ Therapeutics to Report First Quarter Financial Results and Business Update on May 8, 2024
GL
Leerink Partners Starts LENZ Therapeutics With Outperform Rating, $32 Price Target
MT
William Blair Starts LENZ Therapeutics With Outperform Rating
MT
LENZ Therapeutics Reports Positive Topline Data From Late-Stage Presbyopia Trials
MT
LENZ Therapeutics, Inc. Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
CI
Lenz Therapeutics' eye disease drugs meet main goal of late-stage study
RE
LENZ Therapeutics Announces Positive Topline Data from Phase 3 CLARITY Presbyopia Trials
BU
LENZ Therapeutics to Host Investor Call to Discuss Topline Results from the Phase 3 CLARITY Presbyopia Trials
BU
Piper Sandler Initiates LENZ Therapeutics at Overweight With $28 Price Target
MT
LENZ Therapeutics, Inc.(NasdaqGS:LENZ) added to NASDAQ Composite Index
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. LENZ Stock
  4. News LENZ Therapeutics, Inc.